华控康泰(01312) - 2022 - 年度财报

Financial Performance - The Group's revenue for the year ended December 31, 2022, was approximately HK$894.1 million, an increase of approximately 11.3$803.3 million in 2021[14][18]. - The Group reported a loss of approximately HK$52.8 million for the year, compared to a loss of approximately HK$4.6 million in 2021[14][18]. - Basic loss per share amounted to approximately HK$0.74 cent, compared to approximately HK$0.27 cent in the previous year[18]. - The net loss for the year ended December 31, 2022, was approximately HK$109.7 million, an increase of approximately HK$53.4 million compared to the net loss of HK$56.3 million in 2021[44]. - Basic loss per share for 2022 was approximately HK$1.52 cents, compared to HK$0.86 cents in 2021[44]. - The increase in net loss was attributed to higher distribution and selling expenses due to market expansion in the pharmaceutical segment[46]. - The fitness business of the Group generated revenue of approximately HK$171.2 million in 2022, an increase of approximately 6.1% from HK$161.3 million in 2021[74]. - The net loss for the Group's fitness business widened to approximately HK$46.0 million in 2022, compared to HK$26.4 million in 2021[74]. Dividend Policy - The Board has resolved not to recommend any final dividend for the year ended December 31, 2022[19]. - The Company adopted a dividend policy in December 2018, aiming for stable and sustainable returns to shareholders[20]. Business Segments - The Group focuses on human health and aims to create value for all stakeholders through quality services[24]. - The pharmaceutical business segment did not experience supply chain disruptions in 2022, which positively impacted sales, unlike in 2021 when a major supplier failed to deliver on time[41]. - The fitness business segment showed gradual improvement as it overcame the impacts of the COVID-19 pandemic[44]. - Government grants and subsidies related to the COVID-19 pandemic decreased compared to the previous year, impacting the fitness business segment[46]. - The Group plans to focus on the development of its existing advantageous chemical generic medicine and active pharmaceutical ingredients industries[29]. - The Group aims to extend its business reach to emerging sub-sectors to provide better long-term returns to shareholders[29]. Employee and Operational Metrics - The Group had 922 employees as of December 31, 2022, a decrease of 29.4$122.6 million, down from approximately HK$174.2 million in 2021[84]. - The Group's outstanding borrowings repayable within one year were approximately HK$158.8 million as of December 31, 2022, compared to approximately HK$226.7 million in 2021[85]. - The gearing ratio of the Group as of December 31, 2022, was 12.4%, up from 9.5% in 2021[87]. Environmental, Social, and Governance (ESG) Initiatives - The Group's environmental, social, and governance report outlines its commitment to sustainable operations and stakeholder interests[108]. - The Group is committed to operating sustainably, balancing stakeholder interests while positively impacting society[112]. - The ESG Report is prepared based on principles of materiality, quantitative data, balance, and consistency[113]. - The Board oversees the effective implementation of ESG policies, including risk management and performance review[120]. - The Executive Committee and management are responsible for formulating policies and allocating budgets for ESG activities[134]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[134]. - A robust ESG governance structure has been established, consisting of the Board, Executive Committee, management, and working groups[121]. - The Group integrates data from functional departments and subsidiaries to assess ESG performance[135]. - Regular assessments of ESG-related progress and performance are conducted, with reports submitted to the Board[128]. - The Group's strategy focuses on promoting sustainable economies and enhancing value for business partners and shareholders[134]. Waste and Emissions Management - The company aims to reduce gas emissions by regularly conducting exhaust gas monitoring to meet government emission standards, including the Emission Standard of Air Pollutants for Catering Industry and others[162]. - The company has reduced indirect CO2 emissions from electricity consumption to approximately 2,110 tons in 2022, down from 4,034 tons in 2021, with a per capita CO2 density of 3.25 tons[169]. - The company has eliminated heavily-polluted production lines and replaced facilities to reduce emissions, including installing electrostatic fume purifiers and low-nitrogen burners[166]. - The company has upgraded its wastewater treatment system to a three-stage process to further reduce emissions of harmful gases like formaldehyde[168]. - The company has implemented energy-saving actions and purchased new exhaust treatment equipment to enhance emission reduction efforts[168]. - The company has focused on monitoring and controlling the concentration of exhaust gas emissions to ensure compliance with pollutant discharge permits[166]. - The Group has implemented waste sorting and hazardous waste management, signing disposal agreements to enhance treatment efficiency and reduce environmental risks[189]. - The Fitness Business reported no significant emissions of hazardous and non-hazardous wastes in 2022[189]. Renewable Energy Initiatives - A solar energy power generation project has been implemented in the Beijing plant, covering over 30,000 square feet, fulfilling daily energy consumption needs, and selling surplus energy to nearby plants[165]. - The company generated approximately 2,490,000 kWh of clean energy from solar power in 2022, a decrease from approximately 3,910,000 kWh in 2021[198]. - The total electricity consumption for the year 2022 was 6.99 million kWh, down from 13.36 million kWh in 2021, with a per capita electricity consumption density of 0.0108 million kWh[200]. - The company has implemented energy-saving measures, including phasing out high-energy-consuming refrigeration equipment, which has improved production efficiency[200]. Challenges and Market Conditions - Shaanxi Unisplendour faced challenges due to rising raw material prices and the lingering effects of the COVID-19 pandemic[65]. - Chongqing Kangle experienced negative impacts from rising raw material prices and extreme weather conditions in 2022[69]. - The overall operation of Tongfang Pharmaceutical returned to normal levels in 2022, aided by the absence of major product supplier delivery failures[58].